Alternative chemoradiotherapy in anal carcinoma patients with mutations in thymidylate synthase and dihydropyrimidine dehydrogenase genes.
Muhammad Wasif M SaifRuchi HamalNauman SiddiquiAntonia MaloneyMelissa SmithPublished in: Therapeutic advances in gastroenterology (2021)
Molecular testing for DPYD and TYMS genes can allow us to identify patients who are most likely to respond or face severe toxicity to 5-FU in a potentially curable cancer. Combining radiation with CDDP with MMC in patients with AC is feasible. A prospective study based on pharmacogenetic testing comparing MMC/cisplatin with MMC/5-FU is indicated in patients with AC.
Keyphrases
- end stage renal disease
- ejection fraction
- genome wide
- chronic kidney disease
- newly diagnosed
- papillary thyroid
- oxidative stress
- prognostic factors
- early onset
- dna methylation
- genome wide identification
- bioinformatics analysis
- high grade
- gene expression
- radiation induced
- transcription factor
- young adults
- childhood cancer
- patient reported